KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $105.7 million.

  • BeOne Medicines' Accumulated Depreciation & Amortization fell 1301.39% to $105.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.7 million, marking a year-over-year decrease of 1301.39%. This contributed to the annual value of $171.8 million for FY2024, which is 9590.76% up from last year.
  • BeOne Medicines' Accumulated Depreciation & Amortization amounted to $105.7 million in Q3 2025, which was down 1301.39% from $68.4 million recorded in Q2 2025.
  • BeOne Medicines' Accumulated Depreciation & Amortization's 5-year high stood at $171.8 million during Q4 2024, with a 5-year trough of $9.6 million in Q1 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $46.5 million (2021), whereas its average is $56.0 million.
  • In the last 5 years, BeOne Medicines' Accumulated Depreciation & Amortization surged by 9590.76% in 2024 and then plummeted by 1301.39% in 2025.
  • Over the past 5 years, BeOne Medicines' Accumulated Depreciation & Amortization (Quarter) stood at $46.5 million in 2021, then soared by 42.67% to $66.3 million in 2022, then skyrocketed by 32.28% to $87.7 million in 2023, then skyrocketed by 95.91% to $171.8 million in 2024, then tumbled by 38.46% to $105.7 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $105.7 million for Q3 2025, versus $68.4 million for Q2 2025 and $32.8 million for Q1 2025.